Cymbalta Withdrawal & Tapering Guide
duloxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
In short
Cymbalta (duloxetine) is an SNRI with a half-life of 12 hours. Capsules contain enteric-coated pellets. Withdrawal symptoms, when they occur, usually begin 1-2 days after dose reduction and settle within 2-4 weeks for most symptoms. It is also sold as Drizalma, Irenka, Yentreve.
- Class
- SNRI
- Half-life
- 12 hours
- Common doses
- 20mg, 30mg, 60mg, 120mg
- Withdrawal onset
- 1-2 days after dose reduction
- Typical resolution
- 2-4 weeks for most symptoms
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Duloxetine is an SNRI approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. It is known for a difficult discontinuation syndrome.
20mg, 30mg, 60mg, 120mg
Delayed-release capsules: 20mg, 30mg, 60mg
Category C (risk cannot be ruled out)
Mechanism of Action
Potent inhibitor of both serotonin and norepinephrine reuptake (SNRI). Unlike venlafaxine, it inhibits both transporters at standard therapeutic doses. Weak inhibitor of dopamine reuptake.
Taper Notes
Capsules contain enteric-coated pellets. Bead counting possible but pellets are very small.
Hyperbolic Tapering Guidance
Bead counting from capsules for gradual reduction. Some pharmacies can compound liquid formulation.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Use available capsule strengths. Withdrawal symptoms often first appear in this phase. |
| Middle reductions | 6-8 weeks | Ask your prescriber about pellet counting or compounded formulations for more gradual adjustments. |
| Lower dose reductions | 8-10 weeks | Compounding pharmacies can prepare suspensions. Discuss options with your prescriber. |
| Final reductions | 8-12 weeks | Very gradual approach needed. Work closely with your prescriber — do not rush this phase. |
Withdrawal Timeline
1-2 days after dose reduction
3-5 days
2-4 weeks for most symptoms
Brain zaps, nausea, and cognitive fog may persist 2-4 months. Cymbalta discontinuation lawsuits have documented the severity of its withdrawal.
Community Tips
Practical insights shared by members tapering Cymbalta. Not medical advice — always consult your prescriber.
- 1Ask your prescriber about pellet counting from Cymbalta capsules for more precise adjustments. Do not crush the enteric-coated pellets.
- 2Some compounding pharmacies can prepare duloxetine liquid suspension — ask your prescriber if this is an option.
- 3Cymbalta withdrawal often includes a distinctive "whooshing" head sensation distinct from classic brain zaps. This is normal and temporary.
- 4Smaller capsule strengths exist but may not be stocked locally. Ask your pharmacy about ordering options.
- 5Track symptoms in your taper journal. Cymbalta withdrawal can be intense — having data helps your prescriber adjust the plan.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) substantially increase duloxetine levels — avoid combination
- CYP2D6 inhibitors increase duloxetine levels
Food Interactions
- Food delays absorption but does not significantly change total exposure
- Avoid heavy alcohol use (hepatotoxicity risk)
Contraindications
- MAOIs within 14 days
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment
Toxicity
Serotonin syndrome with serotonergic combinations. Hepatotoxicity rare but reported. Severe discontinuation syndrome. Avoid in hepatic impairment and heavy alcohol use.
Pharmacokinetics
ADME Profile
Well absorbed, but enteric coating delays absorption (Tmax 6 hours). Bioavailability ~50% (range 32–80%). Food delays Tmax by 6–10 hours and reduces AUC slightly.
~1640 L (~23 L/kg)
Extensively metabolized hepatically via CYP1A2 (primary) and CYP2D6. Numerous metabolites, none pharmacologically active.
Renal (~70% as metabolites, <1% unchanged) and fecal (~20%).
>90% (primarily albumin and alpha-1-acid glycoprotein)
~114 L/hr (apparent oral clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing SNRI medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 30 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (30 mg start) |
|---|---|---|
| Start | 100% | 30 mg |
| Step 1 | 90% | 27 mg |
| Step 2 | 81% | 24.3 mg |
| Step 3 | 73% | 21.9 mg |
| Step 4 | 66% | 19.7 mg |
| Step 5 | 59% | 17.7 mg |
| Step 6 | 53% | 15.9 mg |
| Step 7 | 48% | 14.3 mg |
| Step 8 | 43% | 12.9 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Cymbalta, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Cymbalta
What are the withdrawal symptoms of Cymbalta (duloxetine)?
Common withdrawal symptoms of Cymbalta (duloxetine) include: brain zaps, nausea, dizziness, headache, irritability, insomnia. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Cymbalta (duloxetine)?
Capsules contain enteric-coated pellets. Bead counting possible but pellets are very small. Bead counting from capsules for gradual reduction. Some pharmacies can compound liquid formulation.
How long does Cymbalta withdrawal last?
Cymbalta withdrawal typically begins 1-2 days after dose reduction, peaks around 3-5 days, and resolves within 2-4 weeks for most symptoms. Brain zaps, nausea, and cognitive fog may persist 2-4 months. Cymbalta discontinuation lawsuits have documented the severity of its withdrawal.
Can I stop Cymbalta cold turkey?
Stopping Cymbalta abruptly is not recommended. Its half-life is 12 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Cymbalta stay in your system?
Cymbalta (duloxetine) has a half-life of 12 hours. A drug is mostly cleared after about five half-lives, so Cymbalta is largely out of the body about 3 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
What tips do others have for tapering Cymbalta?
Ask your prescriber about pellet counting from Cymbalta capsules for more precise adjustments. Do not crush the enteric-coated pellets. Some compounding pharmacies can prepare duloxetine liquid suspension — ask your prescriber if this is an option. Cymbalta withdrawal often includes a distinctive "whooshing" head sensation distinct from classic brain zaps. This is normal and temporary. Smaller capsule strengths exist but may not be stocked locally. Ask your pharmacy about ordering options.
Recent discussions about Cymbalta
What members tapering Cymbalta are asking and reporting right now. Personal experience, not medical advice.
- Cymbalta Tapering ThreadThis is the forum for everyone tapering Cymbalta. When you log a check-in in My Taper, it will appear here. That way you can see how others on the same medication are…Based · 8 months ago
- Duloxotine liquid taperingToday i started my compound liquid formula of Duloxotine, they have given me a formula of 0.44mls fourtnightly,,then dropping 5% every fourtnight,, am I doing the right…Debby · today · 20 replies
- Tapering scheduleHorrible time getting off or establishment of schedule for tapering. I’m miserable.WendyA · 5 days ago · 12 replies
- Seeking advice: Psychiatrist’s taper plan for 13 years on 90mg Cymbalta (Duloxetine) with Prozac bridgeHi everyone, I’m looking for feedback on a tapering plan my psychiatrist just prescribed for me. Background: * Medication: Cymbalta (Duloxetine), 90 mg/day * Duration:…Irem · 6 days ago · 7 replies
- Abrupt discontinuation near the end of my taperHello, I thought I'd share my current story since it's been some time since I've posted. After 4 years on the standard dose, I was tapering my duloxetine for about 2.5…Dominic · 12 days ago · 3 replies
Sources & References
Cymbalta (duloxetine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.